NCT07361263 (PHOENIX) is a NA clinical trial of estradiol valerate in AVP Deficiency, sponsored by University Hospital, Basel, Switzerland.

Who is sponsoring NCT07361263?

NCT07361263 is sponsored by University Hospital, Basel, Switzerland.

What drugs are being tested in NCT07361263?

Interventions in NCT07361263: estradiol valerate, esthinylestradiol.

What condition does NCT07361263 study?

NCT07361263 studies AVP Deficiency, Diabetes Insipidus.

Is NCT07361263 still recruiting?

NCT07361263 is currently recruiting now. Last updated 22 January 2026.

Last reviewed 2026-01-22 · How we verify

NCT07361263: PHOENIX

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Plasma Oxytocin in Response to Oral Estradiol Valerate and Ethinylestradiol in Healthy Controls and Patients With AVP-Deficiency

Recruiting now NA Last updated 22 January 2026

What this trial tests

NA trial testing estradiol valerate in AVP Deficiency in 28 participants. Currently enrolling.

Timeline

9 January 2026

Primary endpoint
1 February 2027

1 February 2027

Quick facts

Lead sponsor	University Hospital, Basel, Switzerland
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	diagnostic
Enrollment	28
Start date	9 January 2026
Primary completion	1 February 2027
Estimated completion	1 February 2027
Sites	1 location across Switzerland

Drugs / interventions tested

estradiol valerate (ESTRADIOL VALERATE) — full drug profile →
esthinylestradiol — full drug profile →

Conditions studied

AVP Deficiency — all drugs for AVP Deficiency →
Diabetes Insipidus — all drugs for Diabetes Insipidus →

Sponsor

University Hospital, Basel, Switzerland

Who can join

Adults 18 to 50, any sex, with AVP Deficiency or Diabetes Insipidus. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Relative Change in Plasma Oxytocin
Time frame: From baseline (0 min) to 300 minutes post-dose.
The primary endpoint is the relative change in plasma oxytocin (OXT) concentrations (pg/mL respectively pM) from baseline to the maximum observed value within 300 minutes after administration of oral estradiol valerate (EV) or ethinylestradiol (EE). Baseline is defined as 100% of the initial pre-dose concentration.
Relative Change in Neurophysin-1
Time frame: From baseline (0 min) to 300 minutes post-dose.
The primary endpoint is the relative change in neurophysin-1 (NP-1) concentrations (pg/mL respectively pM) from baseline to the maximum observed value within 300 minutes after administration of oral estradiol valerate (EV) or ethinylestradiol (EE). Baseline is defined as 100% of the initial pre-dose concentration.

Sponsor's own description

The PHOENIX study aims to investigate whether oral estradiol valerate (EV) and ethinylestradiol (EE) can stimulate oxytocin (OXT) and neurophysin-1 (NP-1) release in humans. The goal is to assess their potential as a safe diagnostic stimulation test for oxytocin deficiency, particularly in patients with arginine vasopressin (AVP) deficiency.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of estradiol valerate

Trials testing the same drug.

NCT04002635 — Letrozole for Frozen Embryo Transfer (FET) in Patients With Polycystic Ovary Syndrome (PCOS) · Phase 4 · withdrawn
NCT05189145 — Hormonal Monitoring and Progesterone Adjustment in Frozen Embryo Transfer Cycles · NA · completed
NCT03300518 — Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response Patient · NA · completed

Other University Hospital, Basel, Switzerland trials

Trials by the same sponsor.

NCT07444788 — Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants · Phase 1 · recruiting
NCT07494214 — Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants · Phase 1 · recruiting
NCT07419048 — Artificial Intelligence or Human Hand? Evaluating Inferior Vena Cava Imaging for Hydration Status · recruiting
NCT06978777 — Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity · NA · recruiting
NCT07273630 — Effect of Protein Supplementation and Fluid Restriction on Plasma Sodium Levels in Patients Undergoing Pituitary Surgery · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07361263 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Basel, Switzerland
Last refreshed: 22 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07361263.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing